A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Non-Hospitalized Participants With Influenza A Infection Who Are at Risk of Developing Complications

Last updated:
2026-07-11
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PIMODIVIR IN COMBINATION WITH THE STANDARD-OF-CARE TREATMENT IN ADOLESCENT, ADULT, AND ELDERLY NON-HOSPITALIZED SUBJECTS WITH INFLUENZA A INFECTION WHO ARE AT RISK OF DEVELOPING COMPLICATIONS

Intervention/treatment:
PIMODIVIR (JNJ-63623872, VX-787)
Medical condition:
INFLUENZA
Protocol code:
63623872FLZ3002
Control number:
211908
Status:
Closed
Approved:
January 02, 2018
Date Completed:
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT03381196
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
13 Years to 85 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Senior Director Medical Leader
Organization
Janssen Research & Development, LLC
Phone:
844-434-4210
Sponsor
JANSSEN RESEARCH AND DEVELOPMENT LLC

Locations

Alberta

The Bailey Clinic
Red Deer, Alberta, T4N 6V7

Newfoundland and Labrador

Commonwealth Medical Clinic
Mount Pearl, Newfoundland and Labrador, A1N 1W7

Ontario

Aggarwal and associates Ltd
Brampton, Ontario, L6T 0G1
Bluewater Clinical Research Group Inc.
Sarnia, Ontario, N7T 4X3
Dr. Anil K Gupta Medicine Professional Corporation
Toronto, Ontario, M9V 4B4
SKDS Research Inc.
Newmarket, Ontario, L3Y 5G8

Quebec

Recherche Clinique Sigma Inc.
Québec, Quebec, G1G 4A2

Results

See the results from the trial NCT03381196. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?